Funding for this research was provided by:
Regeneron Pharmaceuticals (IIS VGFTe-AMD-17104)
Received: 22 May 2021
Accepted: 30 January 2022
First Online: 10 February 2022
: This retrospective study received IRB approval from IRBco. (2017-0050-RCOC) and the study adhered to the tenets set forth in the declaration of Helsinki. All of the information and data collected was in accordance with the Health Insurance Portability and Accountability Act (HIPAA).
: Not applicable.
: SA, HR, AP and SG: Are researchers with Adverum, Allergan, Apellis, Chengdu Kanghong, Clearside Biomedical, Genentech/Roche, Gemini Therapeutics, Graybug Vision, Gyroscope, Iveric Bio, Kodiak, Opthea, Regeneron, and REGENXBIO. DK and SC have no competing interests. SA is a consultant with Adverum and received grant support from Regeneron.